CONTEXT THERAPEUTICS INC (CNTX) Stock News
NASDAQ:CNTX - Nasdaq - US21077P1084 - Common Stock - Currency: USD
CNTX Latest News, Press Relases and Analysis
Context Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO Meeting
Context Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO Meeting
Dosing cohort 3 of Phase 1 trial of CTIM-76, a Claudin 6 x CD3 T cell engager Expect to share initial data in the first half of 2026 PHILADELPHIA, June ...
Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical Officer
Context Therapeutics Announces Chief Medical Officer Transition
Board Member Dr. Karen Smith to serve as Interim Chief Medical Officer...
Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical Officer
PHILADELPHIA, May 29, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical...
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PHILADELPHIA, May 12, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical...
Context Therapeutics Reports First Quarter 2025 Operating and Financial Results
Context Therapeutics Reports First Quarter 2025 Operating and Financial Results
CTIM-76 and CT-95 in Phase 1 Clinical Trials Cash and cash equivalents of $89.4 million as of March 31, 2025 Company expects its cash and cash...
Context Therapeutics Announces Chief Medical Officer Transition
Board Member Dr. Karen Smith to serve as Interim Chief Medical Officer
Context Therapeutics Presents Preclinical and Translational Data for CT-95, a Mesothelin Targeting T Cell Engager, at 2025 AACR Annual Meeting
Context Therapeutics Presents Preclinical and Translational Data for CT-95, a Mesothelin Targeting T Cell Engager, at 2025 AACR Annual Meeting
Preclinical data demonstrates unique binding location of CT-95 on mesothelin and avoidance of binding to shed mesothelin Data supports ongoing Phase 1...
Context Therapeutics Doses First Patient in Phase 1 Clinical Trial of CT-95
Context Therapeutics Doses First Patient in Phase 1 Clinical Trial of CT-95
CT-95 is a mesothelin x CD3 T cell engaging bispecific antibody CT-95 is Context’s second T cell engaging bispecific antibody to enter the clinic in 2025...
Context Therapeutics to Participate in Upcoming Investor Conferences
Context Therapeutics to Participate in Upcoming Investor Conferences
PHILADELPHIA, April 01, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage...
Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025
Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025
PHILADELPHIA, March 26, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage...
Context Therapeutics Reports Full Year 2024 Operating and Financial Results
Context Therapeutics Reports Full Year 2024 Operating and Financial Results
CTIM-76 first patient dosed in January 2025 Cash and cash equivalents of $94.4 million as of December 31, 2024 Company expects its cash and cash...
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PHILADELPHIA, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company...
Context Therapeutics to Participate in Upcoming Investor Conferences
Context Therapeutics to Participate in Upcoming Investor Conferences
PHILADELPHIA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing...
Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76
Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76
CTIM-76 Phase 1 trial focused on CLDN6-positive gynecologic and testicular cancers Trial marks key milestone in driving pipeline progress PHILADELPHIA,...
Context Therapeutics Appoints Andy Pasternak as Chairman of the Board of Directors
Context Therapeutics Appoints Andy Pasternak as Chairman of the Board of Directors
Mr. Pasternak brings decades of global pharmaceutical leadership experience Transition further highlights transformation of the Board to lead Context into...
Context Therapeutics Reports Third Quarter 2024 Operating and Financial Results
Context Therapeutics Reports Third Quarter 2024 Operating and Financial Results
Expands pipeline of T cell engaging bispecific antibodies through acquisitions of CT-95, a Mesothelin x CD3 bispecific antibody, and CT-202, a Nectin-4 x...
Context Therapeutics to Participate in Upcoming Investor Conferences in November
PHILADELPHIA, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing...